Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RET fusion |
| Therapy | SY-5007 |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RET fusion | lung non-small cell carcinoma | sensitive | SY-5007 | Phase III | Actionable | In a Phase III trial, first-line treatment with SY-5007 in patients with non-small cell lung cancer harboring RET fusions resulted in a BICR-confirmed object response rate (ORR) of 90%, disease control rate (DCR) of 96.7%, and estimated 15-month progression-free survival (PFS) rate of 68.9% for the key efficacy population (n=61) and an 87.4% ORR, 93.7% DCR, and 65.0% estimated 15-month PFS for the per-protocol population (n=95) (J Clin Oncol 44: 16_Suppl, 8639; NCT06031558). | detail... |
| RET fusion | lung non-small cell carcinoma | sensitive | SY-5007 | Phase I | Actionable | In a Phase I trial, SY-5007 therapy was tolerable and led to an objective response rate (ORR) of 57.8% (67/116, 67 partial responses), disease control rate (DCR) of 95.7% (111/116), and median progression-free survival of 21.1 mo in advanced solid tumor patients with RET fusions or alterations, and an ORR of 64.1% (41/64) and DCR of 96.9% (62/64) at the phase II dose in non-small cell lung cancer patients with KIF5B (n=51), CCDC6 (n=12), NCOA4 (n=1), or other RET fusions (n=4) (PMID: 39489747; NCT05278364). | 39489747 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39489747) | First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors. | Full reference... |
| Clinical efficacy and tolerability of the selective RET inhibitor soxataltinib (SY-5007) in advanced RET fusion–positive non–small cell lung cancer (NSCLC): Primary findings from a confirmatory phase III trial. | Full reference... |